336 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22761 | Identified PIK3CA status | Ahmad Hussein Awada | Breast | Novartis | SOLAR-1 CBYL719C2301 | Trial closed | A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment CBYL719C2301 (SOLAR-1) | ahmad.awada@hubruxelles.be | 3 | 3 | |
| 22642 | HSCT, refractory or resistant CMV reactivation | Multiple | Shire | SOLSTICE | Trial closed | A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir | 3 | 3 | |||
| 22680 | Biopsy | Thierry Berghmans | Lung | EORTC | SPECTA | Trial open for recruitment | SPECTA : Screening Cancer Patients for Efficient Clinical Trial Access | ||||
| 29449 | Christos Sotiriou | Breast | SPECTA-BREAST | Trial open for recruitment | SPECTA : Screening Cancer Patients for Efficient Clinical Trial Access - Breast | christos.sotiriou@hubruxelles.be | |||||
| 22617 | CRC, UICC stage IV or high risk stage III independently of the pretreatment received. | Alain Hendlisz | Colon | EORTC | SPECTAcolor | Trial closed | SPECTAcolor - Screening platform of the EORTC for Clinical Trials in Advanced Colorectal cancer | alain.hendlisz@hubruxelles.be | |||
| 28560 | Dirk Van Gestel | Multiple | Bordet | STOMRAY | Trial open for recruitment | Prospective pilot study evaluating dental side effects of radiotherapy on subjects treated for head and neck cancer | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | ||
| 22737 | 1st line | Tatiana Dragan | OroPharynx | Institut Jules Bordet | SwallPEG | Trial open for recruitment | Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive radiotherapy and systemic therapy (SwallPEG ; IJB-RT-HNC-001) | accueil.cons.radiotherapie@hubruxelles.be | 3 | 3 | |
| 29421 | RARA-positive, Newly diagnosed with HR-MDS, bone marrow blasts > 5%, adequate organ function | Chloé Spilleboudt | Syndromes myélodysplasiques (MSD) | SYROS Pharmaceuticals, Inc | SY-1425-301 | Trial open for recruitment | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome | chloe.spilleboudt@hubruxelles.be | 3 | 3 | |
| 22738 | 5T4 positive tumors (IHC++/+++) | Nuria Kotecki | Multiple | Byondis | SYD1875.001 | Trial closed | A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours (SYD1875.001) | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 23023 | RECIST v1.1 | Philippe Aftimos | Multiple | Synthon Biopharmaceuticals | SYD985.004 | Trial closed for recruitment | A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22663 | 2nd to 6th line / at least 1 measurable imaging lesion >=2,0cm /archived or fresh biopsy available / no prior treatment with BCL2 inhibitors | Dominique Bron | Lymphoma | Pharmacyclics, Inc. | SYMPATICO | Trial closed for recruitment | Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma | dominique.bron@hubruxelles.be | 3 | 3 | |
| 29777 | Andrea Gombos | Breast | Pfizer | TACTIVE-U | Trial open for recruitment | An interventional safety and efficacy phase 1B/2, open-label umbrella study to investigate tolerability, PK, and antitumor activity of vepdegestrant (AVR-471/PF-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 and older with ER+ advanced or metastatic breast cancer, sub-study C (AVR-471 in combination with samuraciclib | accueil.oncologie@hubruxelles.be | 1/2 | 1 | ||
| 29059 | Spyridon Sideris | prostate | Pfizer | Talapro-3 | Trial closed for recruitment | Talapro-3: A Phase 3, Randomized, Double-Blind, Study Of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide In Men With Ddr Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | spyridon.sideris@hubruxelles.be | 3 | 3 | ||
| 28625 | Mutation FGFR(1-4) | Philippe Aftimos | Multiple | TAIHO Pharmaceutical Co. Ltd | TAS-120-202 | Trial open for recruitment | A Phase 2 Study of TAS-120 in Patients with Specific FGFR (Fibroblast Growth Factor Receptor) Aberrations | philippe.aftimos@hubruxelles.be | 2 | 2 |